Prophylaxis of Iodinated Contrast Media-Induced Nephropathy: A Pharmacological Point of View

Investigative Radiology

Volumn 39, Issue 3, 2004, Pages 155-170

  Idée, Jean Marc ^a,b   Lancelot, Eric ^a   Pines, Emmanuelle ^a   Corot, Claire ^a  

^a Laboratoire Guerbet   (France)

^b Research Division   (France)

Author keywords

Acute renal failure; Contrast media; Pharmacological prophylaxis

Indexed keywords

8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ACETYLCYSTEINE; ADENOSINE RECEPTOR BLOCKING AGENT; AMINOPHYLLINE; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIURETIC AGENT; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM; FUROSEMIDE; IODINATED CONTRAST MEDIUM; MANNITOL; NIFEDIPINE; PROSTAGLANDIN E1 DERIVATIVE; THEOPHYLLINE; VERAPAMIL;

ACUTE KIDNEY FAILURE; CONTRAST NEPHROPATHY; DRUG MECHANISM; GANGRENE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYDRATION; INTESTINE ISCHEMIA; ISCHEMIA; KIDNEY DISEASE; KIDNEY FAILURE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TACHYCARDIA;

EID: 1342344636     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000101483.60710.2c     Document Type: Review

References (152)

1. Katzberg RW. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology. 1997;204:297-312.
2. Idée JM, Beaufils H, Bonnemain B. Iodinated contrast media-induced nephropathy: pathophysiology, clinical aspects and prevention. Fundam Clin Pharmacol. 1994;8:193-206.
3. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA. 1996;275:1489-1494.
4. Gruberg I, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542-1548.
5. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188:171-178.
6. Erley C. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant. 1999;14:1064-1066.
7. Nygren A, Ulfendahl HR. Effects of high- and low-osmolar contrast media on renal plasma flow and glomerular filtration rate in euvolaemic and dehydrated rats. Acta Radiol. 1989;30:383-389.
8. Heyman SN, Brezis M, Greenfeld Z, et al. Protective role of furosemide and saline in radiocontrast-induced acute renal failure in the rat. Am J Kidney Dis. 1989;14:377-385.
9. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR. 1981;136:859-861.
10. Kerstein MD, Puyau FA. Value of periangiography hydration. Surgery. 1984;96:919-922.
11. Dudzinski PJ, Petrone AF, Persoff M, et al. Acute renal failure following high dose excretory urography in dehydrated patients. J Urol. 1971;106:619-621.
12. Byrd L, Sherman RL. Radiocontrast-induced acute renal failure: a clinical and pathophysiologic review. Medicine. 1979;58:270-279.
13. Mueller C, Buerke G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162:329-336.
14. Eloy R, Corot C, Belleville J. Contrast media for angiography: physicochemical properties, pharmacokinetics and biocompatibility. Clin Mat. 1991;7:89-197.
15. Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-184.
16. Weiner IM. Diuretics and other agents employed in the mobilization of edema fluid. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. New York: Pergamon; 1990:713-731.
17. Romano G, Favret G, Federico E, et al. The site of action of furosemide. Pharmacol Res. 1998;37:409-419.
18. Brezis M, Agmon Y, Epstein FH. Determinants of intrarenal oxygenation. I. Effects of diuretics. Am J Physiol. 1994;267:F1059-F1062.
19. Barthelmebs M, Stephan D, Fontaine C, et al. Vascular effects of loop diuretics: an in vivo and in vitro study in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1994;349:209-216.
20. Heyman SN, Brezis M, Reubinoff CA, et al. Acute renal failure with selective medullary injury in the rat. J Clin Invest. 1988;82:401-412.
21. Conger JD. Interventions in clinical acute renal failure: what are the data? Am J Kid Dis. 1995;26:565-576.
22. Better OS, Rubinstein I, Winaver JM, et al. Mannitol therapy revisited. Kidney Int. 1997;51:886-894.
23. Seely JF, Dirks JH. Micropuncture study of hypertonic mannitol diuresis in the proximal and distal tubule of the dog kidney. J Clin Invest. 1969;48:2330-2340.
24. Gennari FJ, Kassirer JP. Osmotic diuresis. N Engl J Med. 1974;291:714-720.
25. Cronin RE, Erickson AB, DeTorrente A, et al. Norepinephrine-induced acute renal failure: a reversible ischemic model of acute renal failure. Kidney Int. 1978;14:187-193.
26. Vari RC, Natarajan LA, Whitescarver SA, et al. Induction, prevention and mechanisms of contrast media-induced acute renal failure. Kidney Int. 1988;33:699-707.
27. Liss P, Nygren A, Ulfendahl HR, et al. Effect of furosemide or mannitol before injection of a non-ionic contrast medium on intrarenal oxygen tension. In: Eke A, Delpy DT, eds. Oxygen Transport to Tissue XXI. New York: Kluwer Academic-Plenum Publishers: 1999:353-359.
28. Liss P, Nygren A, Olsson U, et al. Effects of contrast media and mannitol on renal medullary blood flow and red cell aggregation in the rat kidney. Kidney Int. 1996;49:1268-1275.
29. Anto HR, Chou SY, Porush JG, et al. Infusion intravenous pyelography and renal function. Effects of hypertonic mannitol in patients with chronic renal insufficiency. Arch Intern Med. 1981;141:1652-1656.
30. Weisberg LS, Kurnik PB, Kurnik BRC. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45:259-256.
31. Cohen R. Dysfunction of the vascular endothelium in diabetes mellitus. Circulation. 1993;87(Suppl):V67-V76.
32. Pflueger AC, Larson TS, Hagl S, et al. Role of nitric oxide in intrarenal hemodynamics in experimental diabetes mellitus in rats. Am J Physiol. 1999;277:R725-R733.
33. Louis BM, Hoch BS, Hernandez C, et al. Protection from the nephrotoxicity of contrast dye. Ren Fail. 1996;18:639-646.
34. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-1420.
35. Vliestra RE, Nunn CM, Narvarte J, et al. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J. 1996;132:1049-1050.
36. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy. Results of the P. R. I. N. C. E. study. J Am Coll Cardiol. 1999;33:403-411.
37. McFadzean I, Gibson A. The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle. Br J Pharmacol. 2002;135:1-13.
38. Sanders KM. Mechanism of calcium handling in smooth muscles. J Appl Physiol 2001;91:1438-1449.
39. Rodicio JL, Morales JM, Ruilope LM. Calcium antagonists and the kidney. Nephrol Dial Transplant 1990;5:81-86.
40. Dishart MK, Kellum JA. An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure. Drugs 2000;59:79-91.
41. Hayashi, Nagahama, Oka K, et al. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res. 1996;19:31-36.
42. Fassi A, Sangalli F, Colombi F, et al. Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. Am J Kidney Dis. 1999;33:267-275.
43. Rodicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol. 2000;35:S7-S11.
44. Malis CD, Cheung JY, Leaf A, et al. Effects of verapamil in models of ischemic acute renal failure in the rat. Am J Physiol. 1983;245:F7356-F742.
45. Bakris GL, Burnett JC. A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int. 1985;27:465-468.
46. Wang YXJ, Jia YF, Chen KM, et al. Radiographic contrast media-induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol. 2001;74:1103-1108.
47. Pourrat JP, Douste-Blazy P. Renal side effects of nifedipine. Clin Cardiol. 1984;7:29-30.
48. Cacoub P, Deray G, Baumelou A, et al. No evidence for protective effects of nifedipine against radiocontrast-induced acute renal failure. Clin Nephrol. 1988;29:215-216.
49. Neumayer HH, Junge W, Küfner A, et al. Prevention of radiocontrast media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant. 1989;4:1030-1036.
50. Russo D, Testa A, Della Volpe L, et al. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron. 1990;55:254-257.
51. Russo D, Minutolo R, Cianciaruso B, et al. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol. 1995;6:1451-1458.
52. Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy. 1995;15:59-65.
53. Spångberg-Viklund B, Berglund J, Nikonoff T, et al. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand J Urol Nephrol. 1996;30:63-68.
54. Carraro M, Mancini W, Artero M, et al. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol Dial Transplant. 1996;11:444-448.
55. Seyss C, Foote EF. Calcium-channel blockers for prophylaxis of radiocontrast-associated nephrotoxicity. Ann Pharmacother. 1995;29:187-188.
56. Frishman WH. Calcium channel blockers. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York: Mc Graw-Hill; 1998:73-106.
57. Morris DL, Wisneski JA, Gertz EW, et al. Potentiation by nifedipine and diltiazem of the hypotensive response after contrast angiography. J Am Coll Cardiol. 1985;6:785-791.
58. Pflueger A, Larson TS, Nath KA, et al. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc. 2000;75:1275-1283.
59. Bell PD, Reddington M. Intracellular calcium in the transmission of the tubuloglomerular feed-back signals. Am J Physiol. 1983;245:F25-F32.
60. Osswald HM, Nabakowski G, Hermes H. Adenosine as a possible mediator of metabolic control of glomerular filtration rate. Int J Biochem. 1980;12:263-267.
61. Thomson SC. Adenosine and purinergic mediators of tubuloglomerular feedback. Curr Opin Nephrol Hypertens. 2002;11:81-86.
62. Heyman SN, Clark BA, Kaiser N, et al. Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol. 1992;3:58-65.
63. Deray G, Martinez F, Cacoub P, et al. A role for adenosine calcium and ischemia in radiocontrast-induced intrarenal vasoconstriction. Am J Nephrol. 1990;10:316-322.
64. Lancelot E, Idée JM, Laclédère C, et al. Effects of two dimeric iodinated contrast media on renal medullary blood perfusion and oxygenation in dogs. Invest Radiol. 2002;37:368-375.
65. Erley CM, Heyne N, Burgert K, et al. Prevention of radiocontrast-induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency. J Am Soc Nephrol. 1997;8:1125-1132.
66. Vassalo R, Lipsky JJ. Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clin Proc. 1998;73:346-354.
67. Arakawa K, Suzuki H, Naitoh M, et al. Role of adenosine in the renal responses to contrast medium. Kidney Int. 1996;49:1199-1206.
68. Oldroyd SD, Fang L, Haylor JL, et al. Effects of adenosine receptors antagonists on the responses to contrast media in the isolated rat kidney. Clin Sci. 2000;98:303-311.
69. 1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency. Eur J Pharmacol. 2001;414:99-104.
70. Thompson CI, Sparks HV, Spielman WS. Renal handling and production of plasma and urinary adenosine. Am J Physiol. 1985;248:F545-F551.
71. Arend LJ, Bakris GL, Burnett JCJr., et al. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med. 1987;110:406-411.
72. Katholi RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology. 1995;195:17-22.
73. Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int. 1994;45:1425-1431.
74. Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol. 1998;11:151-156.
75. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol. 1999;83:260-263.
76. Erley CM, Duda SH, Rehfuss D, et al. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant. 1999;14:1146-1149.
77. Shammas NW, Kapalis MJ, Harris M, et al. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invas Cardiol. 2001;13:738-740.
78. Huber W, Jeschke B, Page M, et al. Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk. Intensive Care Med. 2001;27:1200-1209.
79. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology. 2002;223:772-779.
80. Lameire N, Vanholder R. Pathophysiologic features and prevention of human and experimental acute tubular necrosis. J Am Soc Nephrol. 2001;12:S20-S32.
81. Jose PA, Eisner GM, Felder RA. Renal dopamine and sodium homeostasis. Curr Hypertens Res. 2000;2:174-183.
82. Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int. 1996;50:4-14.
83. Hans B, Hans SS, Mittal VK, et al. Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency. Radiology. 1990;176:651-654.
84. Hall KA, Wong RW, Hunter GC, et al. Contrast-induced nephropathy: the effects of vasodilator therapy. J Surg Res. 1992;53:317-320.
85. Weisberg LS, Kurnik PB, Kurnik BRC. Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. Ren Fail. 1993;15:61-68.
86. Kapoor A, Sinha N, Sharma RK, et al. Use of dopamine in prevention of contrast-induced acute renal failure. A randomised study. Int J Cardiol. 1996;53:233-236.
87. Hans SS, Hans BA, Dhillon R, et al. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg. 1998;64:432-436.
88. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol. 1999;34:1682-1688.
89. Nichols AJ, Ruffolo RRJr., Brooks DP. The pharmacology of fenoldopam. Am J Hypertens 1990;3:116S-119S.
90. Kohli JD, Glock D, Goldberg LI. Relative DA1-dopamine-receptor agonist and alpha-adrenoreceptor antagonist activity of fenoldopam in the anesthetized dog. J Cardiovasc Pharmacol. 1988;11:123-126.
91. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. Kidney Int. 1999;56:206-210.
92. Kini AS, Mitre CA, Kamran M, et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol. 2002;89:999-1002.
93. Kini AS, Mitre CA, Kim M, et al. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Cath Cardiovasc Interv. 2002;55:169-173.
94. Madyoon H, Croushore L, Weaver D, et al. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Cath Cardiovasc Interv. 2001;53:341-345.
95. Tumlin JA, Wang A, Murray PT, et al. Fenoldopam mesylate blocks reduction in renal plasma flow after radiocontrast dye: a pilot trial in the prevention of contrast nephropathy. Am Heart J. 2002;143:894-903.
96. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Cath Cardiovasc Interv. 2002;57:279-283.
97. Stone GW, McCullough P, Tumlin J, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290:2284-2291.
98. Oldroyd SD, Morcos SK. Endothelin: what does the radiologist need to know? Br J Radiol. 2000;73:1246-1251.
99. Naicker S, Bhoola KD. Endothelins: vasoactive modulators of renal function in health and disease. Pharmacol Ther. 2001;90:61-88.
100. Benigni A, Perico N, Remuzzi G. Endothelin antagonists and renal protection. J Cardiovasc Pharmacol. 2000;35(Suppl. 2):S75-S78.
101. Clark BA, Kim D, Epstein FH. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis. 1997;30:82-86.
102. Oldroyd SD, Haylor JL, Morcos SK. Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media. Radiology. 1995;196:661-665.
103. Brooks DP, DePalma PD. Blockade of radiocontrast-induced nephrotoxicity by the endothelin receptor antagonist, SB 209670. Nephron. 1996;72:629-636.
104. Oldroyd S, Slee SJ, Haylor J, et al. Role for endothelin in the renal responses to radiocontrast media in the rat. Clin Sci. 1994;87:427-434.
105. Pollock DM, Polakowski JS, Wegner CD, et al. Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy. Ren Fail. 1997;19:753-761.
106. Bird JE, Giancarli MR, Megill JR, et al. Effects of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors. J Am Soc Nephrol. 1996;7:1153-1157.
107. Wang A, Holcslaw T, Bashore TM, Freed MI, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. 2000;57:1675-1680.
108. Haylor JL, Morcos SK. Endothelin antagonism and contrast nephropathy. Kidney Int. 2000;58:2239.
109. Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med. 2000;109:655-678.
110. Stohs SJ. The role of free radicals in toxicity and disease. J Basic Clin Physiol Pharmacol. 1995;6:205-228.
111. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990;258:F115-F120.
112. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int. 1992;41:1008-1015.
113. Katholi RE, Woods T, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32:64-71.
114. Lapenna D, De Gioia S, Mezzetti A, et al. Aminophylline: could it act as an antioxidant in vivo? Eur J Clin Invest. 1995;25:464-470.
115. Kelly GS. Clinical applications of N-acetylcysteine. Altern Med Rev. 1998;3:114-127.
116. Aruoma OI, Halliwell B, Hoey BM, et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6:593-597.
117. Zhang H, Spapen H, Nguyen DN, et al. Effects of N-acetyl-L-cysteine on regional blood flow during endotoxic shock. Eur Surg Res. 1995;27:292-300.
118. Heyman SN, Goldfarb M, Shina A, et al. N-acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int. 2003;63:634-641.
119. Sochman J. N-acetylcysteine in acute cardiology: 10 years later. What do we know and what would we like to know?! J Am Coll Cardiol. 2002;39:1422-1428.
120. Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. Invest Radiol. 2002;37:428-434.
121. Diaz-Sandoval LJ, Kosowsky BD, et al. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89:356-358.
122. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383-1388.
123. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289:553-558.
124. Baker CSR, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114-2118.
125. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40:298-303.
126. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202-2207.
127. Boccalandro F, Amhad M, Smalling RW, et al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv. 2003;58:336-341.
128. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.
129. Thomsen HS. Contrast medium-induced nephrotoxicity: are all answers in for acetylcysteine? Eur Radiol. 2001;11:2351-2353.
130. Kurnik BRC, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998;31:674-680.
131. Ray JG. Prostaglandin E1 analogs do not improve renal function among either transplant or nontransplant patients: no further trials required. Transplantation. 1998;66:476-483.
132. Koch JA, Plum J, Grabensee B, et al. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant. 2000;15:43-49.
133. Gupta RK, Kapoor A, Tewari S, et al. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J. 1999;51:521-526.
134. Di Pasquale P, Valdes L, Albano V, et al. Early captopril treatment reduces plasma endothelin concentrations in the acute and subacute phases of myocardial infarction: a pilot study. J Cardiovasc Pharmacol. 1997;29:202-208.
135. Hoitsma AJ, Wetzels JF, Koene RA. Drug-induced nephrotoxicity. Aetiology, clinical features and management. Drug Safety. 1991;6:131-147.
136. Bauer JH, Reams GP. Antihypertensive drugs. In: Brenner BM, Rector FC, eds. The Kidney. Philadelphia: WB Saunders Co; 1991;2148-2185.
137. Touati C, Idée JM, Deray G, et al. Modulation of the renal effects of contrast media by endothelium-derived nitric oxide in the rat. Invest Radiol. 1993;28:814-820.
138. Blum M, Yachnin T, Wollman Y, et al. Low nitric oxide production in patients with chronic renal failure. Nephron. 1998;79:265-268.
139. Miller HI, Dascalu A, Rassin TA, et al. Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure. Am J Nephrol. 2003;23:91-95.
140. Idée JM, Bonnemain B. Reliability of experimental models of iodinated contrast media-induced acute renal failure. From methodological considerations to pathophysiology. Invest Radiol. 1996;31:230-241.
141. Hierholzer K. Value and necessity of animal research in nephrology. Expl Biol Med. 1982;7:88-101.
142. Shimada T, Mimura M, Inoue K, et al. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys and humans. Arch Toxicol. 1997;71:401-408.
143. Lieberthal W, Nigam SK. Acute renal failure. II. Experimental models of acute renal failure: imperfect but indispensable, Am J Physiol. 2000;278:F1-F12.
144. Lancelot E, Idée JM, Couturier V, et al. Influence of the viscosity of iodixanol on medullary and cortical blood flow in the rat kidney: a potential cause of nephrotoxicity. J Appl Toxicol. 1999;19:341-346.
145. Deray G. Effects of iodixanol on renal function immediately after abdominal angiography. Clinical comparison with iomeprol and ioxaglate (letter). Acta Radiol. 1999;40:111-112.
146. Weisberg LS, Kurnik PB, Kurnik BRC. Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int. 1992;41:1408-1415.
147. Lindholt JS. Radiocontrast-induced nephropathy. Eur J Vasc Endovasc Surg. 2003;25:296-304.
148. Becker JA. Evaluation of renal function. Radiology. 1991;179:337-338.
149. Clark R, Mortensen D, Rabkin R. Recovery from acute renal failure is accelerated by des-(1,3)-insulin-like growth factor-1. Clin Sci. 1994;86:709-714.
150. Guler HP, Eckardt KU, Zapf J, et al. Insulin-like growth factor 1 increases glomerular filtration rate and renal plasma flow in man. Acta Endocrinol. 1989;121:101-106.
151. Fuchs S, Yaffe R, Beeri R, et al. Failure of insulin-like growth factor 1 to improve radiocontrast media-induced nephropathy. Exp Nephrol. 1997;5:88-94.
152. Symon Z, Fuchs Agmon Y, et al. The endogenous insulin-like growth factor system in radiocontrast nephropathy. Am J Physiol. 1998;274:F490-F497.